Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives

被引：46

作者：

Herbreteau, Guillaume ^{[1
]}

Vallee, Audrey ^{[1
]}

Charpentier, Sandrine ^{[1
]}

Normanno, Nicola ^{[2
]}

Hofman, Paul ^{[3
,4
,5
]}

Denis, Marc G. ^{[1
]}

机构：

[1] Nantes Univ Hosp, Dept Biochem, 9 Quai Moncousu, F-44093 Nantes, France

[2] Fdn G Pascale, IRCCS, Ist Nazl Tumori, Cell Biol & Biotherapy Unit, Naples, Italy

[3] Univ Cote Azur, CHU Nice, CNRS 7284, INSERM,Lab Clin & Expt Pathol,U1081, Nice, France

[4] Pasteur Hosp, FHU OncoAge, Nice, France

[5] Pasteur Hosp, Hosp Integrated Biobank BB 0033 00025, Nice, France

来源：

JOURNAL OF THORACIC DISEASE | 2019年 / 11卷

关键词：

Circulating tumor DNA (ctDNA); non-small cell lung cancer (NSCLC); EGFR mutation; ALK translocation; tumor mutation burden (TMB); minimal residual disease (MRD); MOLECULAR TESTING GUIDELINE; T790M RESISTANCE MUTATION; OF-AMERICAN-PATHOLOGISTS; EGFR MUTATION; LIQUID BIOPSY; ACQUIRED-RESISTANCE; ADENOCARCINOMA PATIENTS; CEREBROSPINAL-FLUID; ALK REARRANGEMENT; BRAF MUTATION;

D O I：

10.21037/jtd.2018.12.18

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Major advances in the treatment of non-small cell lung cancer (NSCLC) patients have been obtained during the last decade. Molecular testing of tumor samples is therefore mandatory in routine clinical practice. Tumor DNA is also present as cell-free molecules in blood, which is therefore a very useful and convenient source of tumor DNA. In this review, we discuss pre-analytical and analytical aspects of circulating tumor DNA (ctDNA) analysis. We also describe the use of ctDNA analysis in routine clinical practice, and discuss the potential use of ctDNA monitoring both to identify minimal residual disease and as a potential tool to early identify patients' response to treatment.

引用

页码：S113 / S126

页数：14

共 132 条

[31] Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA [J].

Goldberg, Sarah B. ;

Narayan, Azeet ;

Kole, Adam J. ;

Decker, Roy H. ;

Teysir, Jimmitti ;

Carriero, Nicholas J. ;

Lee, Angela ;

Nemati, Roxanne ;

Nath, Sameer K. ;

Mane, Shrikant M. ;

Deng, Yanhong ;

Sukumar, Nitin ;

Zelterman, Daniel ;

Boffa, Daniel J. ;

Politi, Katerina ;

Gettinger, Scott N. ;

Wilson, Lynn D. ;

Herbst, Roy S. ;

Patel, Abhijit A. .

CLINICAL CANCER RESEARCH, 2018, 24 (08) :1872-1880

[32] Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer [J].

Guibert, N. ;

Hu, Y. ;

Feeney, N. ;

Kuang, Y. ;

Plagnol, V. ;

Jones, G. ;

Howarth, K. ;

Beeler, J. F. ;

Paweletz, C. P. ;

Oxnard, G. R. .

ANNALS OF ONCOLOGY, 2018, 29 (04) :1049-1055

[33] Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma [J].

Guibert, Nicolas ;

Pradines, Anne ;

Casanova, Anne ;

Farella, Magali ;

Keller, Laura ;

Soria, Jean-Charles ;

Favre, Gilles ;

Mazieres, Julien .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (09) :E109-E112

[34] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

[35]

Herbreteau Guillaume, 2018, Oncotarget, V9, P25265, DOI 10.18632/oncotarget.25404

[36] Circulating tumour DNA: analytical aspects and clinical applications for metastatic melanoma patients [J].

Herbreteau, Guillaume ;

Vallee, Audrey ;

Knol, Anne-Chantal ;

Theoleyre, Sandrine ;

Quereux, Gaelle ;

Khammari, Amir ;

Dreno, Brigitte ;

Denis, Marc G. .

ANNALES DE BIOLOGIE CLINIQUE, 2017, 75 (06) :619-630

[37] Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer [J].

Hu, Wenwei ;

Yang, Yang ;

Zhang, Longzhen ;

Yin, Jianxin ;

Huang, Jingwei ;

Huang, Lei ;

Gu, Hua ;

Jiang, Gening ;

Fang, Jianmin .

CANCER MEDICINE, 2017, 6 (05) :962-974

[38] Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer [J].

Hyun, Myung Han ;

Sung, Jae Sook ;

Kang, Eun Joo ;

Choi, Yoon Ji ;

Park, Kyong Hwa ;

Shin, Sang Won ;

Lee, Sung Yong ;

Kim, Yeul Hong .

ONCOTARGET, 2017, 8 (55) :94417-94430

[39] Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer [J].

Isbell, James M. ;

Jones, David R. ;

Li, Bob T. .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (06) :2628-2631

[40] Tracking the Evolution of Non-Small-Cell Lung Cancer [J].

Jamal-Hanjani, M. ;

Wilson, G. A. ;

McGranahan, N. ;

Birkbak, N. J. ;

Watkins, T. B. K. ;

Veeriah, S. ;

Shafi, S. ;

Johnson, D. H. ;

Mitter, R. ;

Rosenthal, R. ;

Salm, M. ;

Horswell, S. ;

Escudero, M. ;

Matthews, N. ;

Rowan, A. ;

Chambers, T. ;

Moore, D. A. ;

Turajlic, S. ;

Xu, H. ;

Lee, S. -M. ;

Forster, M. D. ;

Ahmad, T. ;

Hiley, C. T. ;

Abbosh, C. ;

Falzon, M. ;

Borg, E. ;

Marafioti, T. ;

Lawrence, D. ;

Hayward, M. ;

Kolvekar, S. ;

Panagiotopoulos, N. ;

Janes, S. M. ;

Thakrar, R. ;

Ahmed, A. ;

Blackhall, F. ;

Summers, Y. ;

Shah, R. ;

Joseph, L. ;

Quinn, A. M. ;

Crosbie, P. A. ;

Naidu, B. ;

Middleton, G. ;

Langman, G. ;

Trotter, S. ;

Nicolson, M. ;

Remmen, H. ;

Kerr, K. ;

Chetty, M. ;

Gomersall, L. ;

Fennell, D. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (22) :2109-2121

← 1 2 3 4 5 6 7 8 9 10 →